Summary Cisplatinum may prove to be a valuable agent for the elimination of diseased cells in the bone marrow of patients with neuroblastoma. In this study, we measured the efficacy of cisplatinum on human neuroblastoma cell lines and on normal human bone marrow progenitors, GM-CFC and CFU-F. Data indicate that the therapeutic index of cisplatinum is high. We set up an experimental model consisting of a mixture of human bone marrow and human neuroblastoma cells in order to confirm these preliminary results in purging conditions. Results indicate that cisplatinum exhibits a high and specific tumoricidal property and appears to be valid in bone marrow purging.
The relationship between drug-dose and therapeutic efficacy in the treatment of neuroblastoma (NB) has led to the use of high-dose chemotherapy with autologus bone marrow transplantation (ABMT) (Hartmann el al., 1985; Laporte et al., 1987) . The therapeutic benefits of ABMT in the treatment of NB are offset by the possible reinjection of malignant cells in the patient because NB very frequently exhibit bone marrow involvement. Even when the marrow is collected in complete remission, the risk of contamination due to the presence of residual disease cannot be excluded (Bayle et al., 1985) .
Various purging techniques have therefore been tested: biological separation (Reisner & Gan, 1985) , immunological procedures using monoclonal antibodies with complement (Saarinen et al., 1985) or conjugated with a toxin (Raso et al., 1982) or with magnetic beads (Trealeaven et al., 1984) . Chemical agents have also been employed in purging procedures. Asta-Z is an active metabolite of cyclophosphamide which has been shown to cure myelogenous leukemia (Sharkis et al., 1980) . It is now routinely used to purge human NB bone marrows before ABMT. Unfortunately bone marrow purging by Asta-Z frequently induces a delay of 7-10 days in the patient's haematological reconstitution (Beaujean et al., 1987) . This adverse effect led us to study a compound exhibiting less myelotoxicity. Our choice focused on cisplatinum, given its moderate myelotoxicity.
Five previous studies concerning cisplatinum (CDDP) have been published. Three of them (Ajani et al., 1986; Ogawa et al., 1975; Umbach et al., 1984) only dealt with the human haematopoietic toxicity of CDDP. The other two were screening studies of its tumoricidal activity (Ajani et al., 1985; Umbach et al., 1985) . No publication has yet described the effect of CDDP on tumour cells and haematopoietic progenitors in routine ABMT purging conditions. We therefore decided to set up an experimental model consisting of a mixture of human neuroblastoma cells in order to evaluate the efficacy of CDDP in purging conditions, but this was preceded by a preliminary experiment which was devoted to the evaluation of CDDP efficacy on NB cell lines alone. The mixture which contained a NB tumour cell line (IGR-N-835) and normal human bone marrow cells at a ratio of 10% was treated with a drug concentration which ranged from 0 to 10 IiM. A (Carney et al., 1981) . This defined medium consists of products dissolved in MEM medium at the following final concentrations: 10-8M hydrocortisone, 5 .g ml-' insulin, 100 I g ml-' human transferrin, 10-8M 17 P-oestradiol, 3 x Io-' M sodium selenite.
Human cell materials Human neuroblastoma cell lines.
Two human neuroblastoma cell lines, SK-N-SH and SK-N-AS, were kindly provided by Dr Helson (Sloan Kettering Institute, New York). The third one, IGR-N-835, was originated in our laboratory and derived from an undifferentiated immature NB of a 2-year-old patient who had undergone intensive chemotherapy treatment (four cycles of cyclophosphamide, doxorubicine and vincristine) and exhibited tumour progression. The IGR-N-835 cells were transferred only 15 times for the experiments conducted for the purposes of the present study.
All lines were cultured at 37°C in 25 cm2 flasks containing MEM-10% heat inactivated fetal calf serum (HIFCS) in an incubator with 7.5% carbon dioxide. The media were changed twice a week. SK-N-SH and SK-N-AS lines were dissociated with 0.25% trypsin-EDTA and the IGR-N-835 cell line with 0.05% trypsin-EDTA, until high cell density was achieved.
Normal bone marrow. Heparinised normal bone marrow samples were obtained from 10 healthy donors after informed consent. The bone marrow cells were separated on a Hypaque-Ficoll gradient. The mononuclear cells were washed twice in a buffered alpha medium and then resuspended at a concentration of 107 cells ml-' in a medium buffered by HEPES.
Measurements of CDDP cytotoxicity to NB cell lines Clonogenic monolayer assays (CMA) were performed. Briefly, 3 x 105 cells of SK-N-SH and SK-N-AS and 9 x 105 cells of IGR-N-835 were seeded in 60 mm culture grade Petri dishes (Nunc) and cultured in MEM-10% HIFCS. Once the exponential phase of growth was reached, viable cells were counted with Trypan blue in three replicate dishes so that the number of cells could be determined as a function of the dose of CDDP. This medium was then replaced using fresh MEM-HITES with 2% HIFCS, and CDDP ranging from 0 to 10 gM was added for 1 h at 37C, 7.5% CO2. After this drug treatment, the cells were trypsinised and cultured in MEM-10% HIFCS in 60mm culture grade Petri dishes for a further 12 days for SK-N-SH and SK-N-AS and a further 21 days for IGR-N-835. Anchored colonies were fixed by methanol and stained with violet crystal. Colonies of more than 50 cells were counted using an image analyser Magiscan II (Joyce Loebel Co.) according to a previously described programme (Kahn et al., 1986) (Bayle et al., 1985) . However, in our mixture, we decided on a ratio of 10% of NB cells so that optimal conditions were achieved with a sufficient number of cell colonies. Tumour cell survival was estimated using a clonogenic assay to explore the possible long-term proliferative capacity of NB cells. In order to evaluate the differential susceptibility of tumour cells according to their concentration in bone marrow mixtures, we carried out another set of experiments using mixtures containing 1% of NB cells and similar results were obtained (data not shown).
With regard to GM-CFC, three studies have been published. Ogawa et al. (1975) pointed out that human cells were less sensitive to CDDP than murine GM-CFC. The other two papers studied human tumour cells and human GM-CFC in the presense of CDDP, but separately (Ajani et al. 1985; Umbach et al., 1985) . None of these studies was performed in ABMT routine purging conditions. High-dose chemotherapy is currently used to eradicate residual disease in NB patients in complete remission . Asta-Z, an active metabolite of cyclophosphamide at 100 yM, is currently used in NB bone marrow purging. Asta-Z treated marrow, however, induces a .~~~~~~i .
-13 . k more prolonged delay in recovery from aplasia; almost 4 weeks versus 2.5 without bone marrow purge (Beaujean et al., 1987) . In order to reconstitute the haematopoietic system after purge in vitro, 108 bone marrow cells per kilogram are reinjected to the patients. If previously harvested bone marrow is contaminated, ABMT procedure cannot be applicable. Maximal proportion of cytologically measureable occult tumour cells in the infused bone marrow sample is less than 0.1%. This means that, for a patient of 70kg, about 10'°b one marrow cells and, possibly, 107 tumour cells are reinjected. Our results show that a dose of 39 ylM of CDDP is an adequate purging dose for 10' tumour cells (Table II) while more than 70% of the GM-CFC and more than 90% of the CFU-F cells remain alive at this dose. Furthermore, CDDP has been shown to induce cell differentiation (Tonini et al., 1986) . Whether this agent is able to induce similar effects on NB cells remains to be elucidated. If CDDP-induced cell differentiation were to be established then this, associated with the apparently direct cytotoxic effect of this agent would provide an extremely powerful means for ridding the marrow of metastatic cells with minimal damage to the bone marrow. It would also be of interest to investigate CDDP toxicity to pluripotential haematopoeitic cells.
